NYSE · VEEV
Healthcare · Medical - Healthcare Information Services
$266.62
Up+$0.95 (+0.36%)
Updated Sep 16, 2026, 10:59 AM
SID Score
6.5/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VEEV closed at $266.62 after 20 trading sessions, up 9.83% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $260.80 | $272.3899 | $258.01 | $266.62 | 1.35M |
| Sep 14, 2026 | $264.93 | $267.4233 | $260.56 | $265.67 | 1.36M |
| Sep 11, 2026 | $261.81 | $263.69 | $259.54 | $262.40 | 863.8K |
| Sep 10, 2026 | $260.99 | $264.58 | $258.1902 | $260.98 | 853.39K |
| Sep 9, 2026 | $266.21 | $266.21 | $259.50 | $260.80 | 1.08M |
| Sep 8, 2026 | $271.62 | $271.65 | $263.91 | $264.84 | 1.47M |
| Sep 4, 2026 | $279.56 | $279.86 | $273.61 | $275.09 | 1.15M |
| Sep 3, 2026 | $284.01 | $288.375 | $277.85 | $284.38 | 1.51M |
| Sep 2, 2026 | $278.28 | $282.43 | $276.05 | $280.72 | 1.49M |
| Sep 1, 2026 | $282.12 | $286.79 | $278.03 | $279.23 | 1.22M |
| Aug 31, 2026 | $274.79 | $290.47 | $273.60 | $285.69 | 2.85M |
| Aug 28, 2026 | $280.00 | $284.68 | $276.45 | $276.69 | 3.64M |
| Aug 27, 2026 | $275.355 | $296.24 | $274.81 | $282.13 | 6.41M |
| Aug 26, 2026 | $239.87 | $247.70 | $238.93 | $244.91 | 1.46M |
| Aug 25, 2026 | $244.27 | $247.85 | $242.53 | $246.78 | 1.62M |
| Aug 24, 2026 | $247.06 | $249.24 | $242.03 | $248.46 | 1.57M |
| Aug 21, 2026 | $250.74 | $250.81 | $246.80 | $247.90 | 1.09M |
| Aug 20, 2026 | $250.00 | $253.4899 | $246.00 | $250.53 | 1.31M |
| Aug 19, 2026 | $243.30 | $252.97 | $242.755 | $251.00 | 1.8M |
| Aug 18, 2026 | $243.17 | $247.025 | $241.72 | $242.75 | 1.52M |
The latest Smart Investors Daily articles mentioning VEEV.
VEEV research
Company profile and research snapshot.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 28, 2026 | Citigroup | Neutral | — |
| Aug 27, 2026 | UBS | Neutral | — |
| Aug 27, 2026 | Barclays | Overweight | — |
| Aug 27, 2026 | TD Cowen | Buy | — |
| Aug 27, 2026 | Canaccord Genuity | Hold | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Veeva Systems Inc. (VEEV) Citi's 2026 Global TMT Conference September 10, 2026 10:50 AM EDTCompany ParticipantsBrian Van Wagener - Chief Financial...
SeekingAlpha · Sep 9, 2026
Yahoo · Sep 8, 2026
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
Yahoo · Sep 7, 2026
Michael Burry remains bullish on Veeva but trimmed his stake after shares jumped more than 15% on a fiscal second-quarter earnings beat and a raised 2027 outlook.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VEEV.
